Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
Globe Newswire22-10-2024, 19:00
Constellation Brands Issues 2023 ESG Impact Report and Announces Enhanced Water Withdrawal Restoration Target Benefitting Local Communities 24-10-2023, 20:00